Companies: 10,795·Total market cap: $144.5T
Apexigen, Inc.

Apexigen, Inc.

APGNNASDAQHealthcare
$0.39
+$0.03(+8.48%)
Market Cap$9574318
P/E Ratio
52W High$8.28
52W Low$0.331
Overview

Apexigen, Inc. (APGN) Market Cap & Net Worth

Live market cap, enterprise value, and global rank — multi-year chart and annual table below.

apgn · market cap & enterprise value · FMP · as of Aug 22, 2023

Core market cap & key metrics

As of Aug 22, 2023, Apexigen, Inc. (APGN) has a market cap — also referred to as its net worth or valuation — of $9,574,318, making it one of the top most valuable companies globally. Market Cap = $0.39 × shares outstanding.

Market Cap (Net Worth)$9,574,318apgn market cap 2026
Enterprise ValuemktCap + debt − cash
1-Year Changevs one year ago
Global Rankinglargest company by mkt cap
All-Time High$0apgn highest market cap ever
Stock Price$0.39NASDAQ · Aug 22, 2023
How is Market Cap calculated?Market Cap = Stock Price × Shares Outstanding

About Market Cap, Net Worth & Valuation

Apexigen, Inc. (APGN) has a market cap — also referred to as its net worth or valuation — of $9,574,318 as of Aug 22, 2023, making it the #0 most valuable company globally. Market Cap = Stock Price × Shares Outstanding.

Apexigen, Inc. reached its all-time high market cap of $0 on —. Comparing the Apexigen, Inc. market cap history illustrates one of the most extraordinary corporate growth stories.

Investors frequently compare Apexigen, Inc. net worth vs peers and ask how Apexigen, Inc. valuation compares to other countries. Its market cap reflects continued investor confidence.

Data: FMP · year-end market cap · not investment advice

Frequently Asked Questions

APGN market cap · 6 questions

Apexigen, Inc.'s net worth — measured as market capitalization — is $9,574,318 as of Aug 22, 2023. It ranks #0 globally. Market Cap = $$0.39 (price) × shares outstanding.

APGN net worth 2026market cap vs book valuelargest companies by market cap
Data: Financial Modeling Prep · Market cap updates daily · For informational purposes only, not investment advice.